Skip to main content

Table 6 Multinominal regression of participants’ beliefs and views about complementary medicines by demographic variables

From: A survey describing the use of complementary therapies and medicines by women attending a family planning clinic

n = 209

OR

95% CI

I only use CM as a last resorta

  

Disagree

  

Age

18–24

1.60

(0.43-6.0)

 

25–34

2.68

(0.58-12.4)

 

35–44

1.38

(0.34-5.63)

 

45+

0b

Tertiary Education

  
 

No

3.26

(0.80-13.3)

 

Yes

0b

 

Don’t know

 

Age

18–24

0.52

(0.16-1.61)

 

25–34

2.11

(0.58-7.67)

 

35–44

0.91

(0.29-2.83)

 

45+

0b

 

Tertiary Education

 
 

No

1.81

(0.48-6.8)

 

Yes

0b

 

CMs are not as risky as prescribed medication

  

Disagree

  

Age

18–24

2.59

(0.84-8.0)

 

25–34

0.68

(0.21-2.1)

 

35–44

1.05-

(0.33-3.35)

 

45+

0b

Tertiary Education

  
 

No

1.08

(0.37-3.15)

 

Yes

0b

 

Don’t know

 

Age

18–24

1.05

(0.40-2.77)

 

25–34

0.61

(0.26-1.43)

 

35–44

0.77

(0.31-1.89)

 

45+

0b

Tertiary Education

 
 

No

1.3

(0.55-3.14)

 

Yes

0b

 

CMs can cause dangerous side effects

  

Disagree

  

Age

18–24

1.73

(0.59-5.03)

 

25–34

0.81

(0.29-2.24)

 

35–44

0.75

(0.26-2.09)

 

45+

0b

Tertiary Education

  
 

No

0.81

(0.31-2.08)

 

Yes

0b

 

Don’t know

  

Age

18–24

1.70

(0.57-5.04)

 

25–34

1.56

(0.60-4.06)

 

35–44

1.17

(0.43-3.12)

 

45+

0b

 

Tertiary Education

 
 

No

0.81

(0.21-1.49)

 

Yes

0b

Ingredients in CM make them safe to use

Disagree

 

Age

18–24

1.72

(0.64-4.6)

 

25–34

0.43

(0.17-1.1)

 

35–44

0.79

(0.30-2.1)

 

45+

0b

Tertiary Education

 
 

No

1.28

(0.49-3.38)

 

Yes

0b

Don’t know

 

Age

18–24

0.74

(0.23-2.37)

 

25–34

0.47

(0.17-1.29)

 

35–44

1.11

(0.30-2.10)

 

45+

0b

Tertiary Education

 
 

No

1.99

(0.73-5.41)

 

Yes

0b

  1. the reference category is agree.
  2. b this parameter is set to zero because it is redundant.
  3. OR, Odds Ratio, CI, confidence interval; CM complementary medicine.